TRAF1/C5 but not PTPRC variants are potential predictors of rheumatoid arthritis response to anti-tumor necrosis factor therapy.
Helena CanhãoAna Maria RodriguesMaria José SantosDiana Carmona-FernandesBruno F BettencourtJing CuiFabiana L RochaJosé Canas SilvaJoaquim Polido-PereiraJosé Alberto Pereira SilvaJosé António CostaDomingos AraujoCândida SilvaHelena SantosCátia DuarteRafael CálizIleana FilipescuFernando Pimentel-SantosJaime BrancoJuan SainzRobert M PlengeDaniel H SolomonJácome Bruges-ArmasJosé António P Da SilvaJoão Eurico FonsecaElizabeth W KarlsonPublished in: BioMed research international (2015)
This study did not replicate the association between PTPRC and the response to anti-TNF treatment in our Southern European population. We found that TRAF1/C5 risk RA variants potentially influence anti-TNF treatment response.